Graphite Bio, Inc. - GRPH STOCK NEWS

Graphite Bio (Nasdaq: GRPH) has formed a new Scientific Advisory Board (SAB) comprising four leading experts in gene therapy and related fields. This board will provide strategic guidance as the company advances its gene editing platform to develop curative therapies. Notable members include Dr. Maria Grazia Roncarolo, a pioneer in gene therapy, and Dr. John E. Dick, a renowned researcher in stem cell biology. The SAB aims to leverage their expertise to enhance Graphite Bio's research and development efforts towards transformative gene therapies.

Graphite Bio (Nasdaq: GRPH) announced the ongoing enrollment for its Phase 1/2 CEDAR clinical trial of GPH101 for sickle cell disease, with patient dosing now set for the second half of 2022 and proof-of-concept data expected in 2023. The company reported $378.7 million in cash as of December 31, 2021, which should fund operations into Q4 2024. Furthermore, the company appointed a new CFO and Chief of Staff, indicating strengthened leadership and focused R&D on next-generation gene editing technologies aimed at transformative patient outcomes.

Graphite Bio, Inc. (NASDAQ: GRPH) announced that CEO Josh Lehrer, M.D., will speak at the Cowen 42nd Annual Health Care Conference on March 8, 2022, at 12:50 p.m. ET. The discussion will focus on gene editing and will be available for live streaming on Graphite Bio's website. The company is engaged in developing targeted gene integration therapies aimed at treating serious diseases. Graphite Bio leverages a unique gene editing platform to correct mutations and replace disease-causing genes.

Graphite Bio (NASDAQ: GRPH) has appointed Alethia Young as Chief Financial Officer, effective April 1. Young previously served as a senior biotech analyst at Cantor Fitzgerald, bringing over 20 years of equity research expertise in healthcare and biotech. In her new role, she will manage finance, investor relations, and corporate communications, playing a pivotal role in the company’s strategy. CEO Josh Lehrer highlighted her extensive industry experience as a vital asset for advancing Graphite Bio's mission in gene editing therapies.

Graphite Bio (Nasdaq: GRPH), a leader in next-generation gene editing, has announced its participation in two significant investor conferences. CEO Josh Lehrer will speak at the Cowen 2nd Annual Genetic Medicines Summit on February 3, 2022, and engage in a fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference on February 17, 2022. Both events reflect Graphite Bio's commitment to advancing gene editing technologies aimed at curing serious diseases. The fireside chat will be available for live streaming on the company's website.

Graphite Bio presented a trial-in-progress poster for its Phase 1/2 CEDAR trial assessing GPH101, a gene therapy targeting sickle cell disease. The therapy aims to correct the genetic mutation causing the disease. Initial proof-of-concept data is expected by the end of 2022. GPH101 has received orphan drug designation from the FDA. This open-label trial will evaluate safety in about 15 participants with severe sickle cell disease, seeking to demonstrate the potential for a curative approach by restoring normal hemoglobin production.

Graphite Bio (NASDAQ: GRPH) will host a virtual Key Opinion Leader webinar on December 14, 2021, at 3 p.m. ET. The session will discuss the company’s gene correction approach with GPH101 for treating sickle cell disease (SCD). Notable speakers include CEO Josh Lehrer and experts from St. Jude Children’s Research Hospital and Stanford University. The webinar will also showcase a poster from the Phase 1/2 CEDAR Trial for GPH101, which highlights the potential of this gene therapy to cure SCD.

Graphite Bio has announced the enrollment of its first patient in the Phase 1/2 clinical trial for GPH101, a gene-edited therapy aimed at correcting the mutation responsible for sickle cell disease (SCD). Treatment is expected to begin in the first half of 2022, with initial proof-of-concept data anticipated by the end of the year. The open-label trial, called CEDAR, will assess safety and effectiveness across approximately 15 participants at five sites in the U.S.

Graphite Bio (GRPH) has commenced recruitment for its Phase 1/2 CEDAR trial of GPH101, targeting sickle cell disease, with plans to enroll the first patient by year-end. Recent preclinical data support GPH101's potential in correcting the genetic mutation responsible for the disease. As of September 30, 2021, the company reported $395 million in cash, enabling ongoing research and development efforts, which incurred $8.7 million in expenses for Q3 2021. The net loss for the quarter was $14.6 million, or $0.28 per share.